Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peptide-I
- Development stage
- Preclinical
- Lead developer
- Peking University First Hospital
- Modality
- Peptides
01
Overview
Peptide-I is a cell-penetrating peptide developed by researchers at Peking University First Hospital to treat myocardial infarction (MI) complicated by stress hyperglycemia (SHG). Under hyperglycemic conditions, the interaction between the transcription factor FOXK2 and O-GlcNAc transferase (OGT) is promoted, leading to site-specific O-GlcNAcylation of FOXK2 at threonine 552, which triggers its polyubiquitination and proteasomal degradation. Peptide-I acts by disrupting the FOXK2–OGT interaction, thereby stabilizing FOXK2, restraining macrophage inflammatory activation (specifically suppressing the IL-6/STAT3 signaling axis), and improving post-infarction cardiac repair and function.
02
Targets
FOXK2 (Forkhead box protein K2)IL-6 (Interleukin 6)OGT (UDP-N-acetylglucosamine—peptide N-acetylglucosaminyltransferase)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on Peptide-I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptide-I.